We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Agilent Launches New Panel for Fast FISH Testing  on Dako Omnis in Lung Cancer
Product News

Agilent Launches New Panel for Fast FISH Testing on Dako Omnis in Lung Cancer

Agilent Launches New Panel for Fast FISH Testing  on Dako Omnis in Lung Cancer
Product News

Agilent Launches New Panel for Fast FISH Testing on Dako Omnis in Lung Cancer


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Agilent Launches New Panel for Fast FISH Testing on Dako Omnis in Lung Cancer"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Agilent Technologies has announced the EU launch of a new CE-IVD labeled IQFISH lung cancer panel for automated analysis on Dako Omnis. The new panel enables routine pathology laboratories to easily integrate fast, high-quality FISH into their IHC workflow. This allows labs to simultaneously stain IHC and FISH slides and enable multiple FISH slides to be processed in just four hours, a process that often takes two days or more with traditional FISH.

The new panel, comprising of ALK, ROS1, RET and MET IQFISH probes, was designed using the groundbreaking, oligonucleotide-based SureFISH technology utilizing formamide-free IQFISH fast hybridization buffer.

"We are excited about the upcoming probe launches for Dako Omnis," said Jacob Thaysen, president of Agilent’s Diagnostics and Genomics Group. "Agilent is committed to improving the speed and accuracy of patient-sample processing and the quality of test performance. We know that these factors greatly affect treatment decisions and patient outcome." 

The lung cancer panel is the second IQFISH launch for Dako Omnis following its introduction of HER2 IQFISH pharmDx in 2015.

Advertisement